Multiple skull base meningioma

Summary

Multiple skull base meningioma (MONDO:0004094) is a disease. A subtype of skull base meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	multiple skull base meningioma
Mondo ID	MONDO:0004094
DOID	DOID:7054
NCIT	C5279
UMLS	C1334829
MedGen	233723
GARD	0023817
Is cancer (heuristic)	no

Disease family

This is a subtype of skull base meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › head and neck neoplasm › skull neoplasm › skull base neoplasm › skull base meningioma › multiple skull base meningioma

Related subtypes (9): cavernous sinus meningioma, foramen magnum meningioma, clivus meningioma, diaphragma sellae meningioma, suprasellar meningioma, petroclival meningioma, sphenoorbital meningioma, sphenocavernous meningioma, pituitary stalk meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.